Literature DB >> 16799915

Methadone metabolism by early gestational age placentas.

Todd Lewis Hieronymus1, Tatiana N Nanovskaya, Sujal V Deshmukh, Ricardo Vargas, Gary D V Hankins, Mahmoud S Ahmed.   

Abstract

The objective of this study was to identify the enzyme that metabolizes methadone in preterm placentas. Microsomal fractions were obtained from preterm (17 to 34 weeks) placentas (36 total; 12 per each gestational age group) and their activity in metabolizing methadone to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) was determined. The enzyme catalyzing the reaction was identified by using chemical inhibitors selective for various cytochrome P450 isozymes and monoclonal antibodies raised against them. The metabolism of methadone by microsomes revealed saturation kinetics. Methadone was N-demethylated to EDDP by aromatase. The affinity of methadone to aromatase (apparent Km) did not change with gestation, but the activity of the enzyme (Vmax) increased and varied widely between individual placentas. Aromatase/CYP19 is the placental enzyme metabolizing methadone during pregnancy. The variability in enzyme activity among individuals should be reflected by the concentration of methadone in the fetal circulation and might be one of the factors affecting the incidence and intensity of neonatal abstinence syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799915     DOI: 10.1055/s-2006-947160

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  6 in total

1.  (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy.

Authors:  Andrea L Gordon; Olga V Lopatko; Andrew A Somogyi; David J R Foster; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

Review 2.  Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.

Authors:  T Lewis; J Dinh; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2015-07-22       Impact factor: 6.875

3.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

4.  Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).

Authors:  Wenjie Jessie Lu; Robert Bies; Landry K Kamden; Zeruesenay Desta; David A Flockhart
Journal:  Drug Metab Dispos       Date:  2010-04-21       Impact factor: 3.922

5.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

6.  Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome.

Authors:  Ingrid F Metzger; Anna E Thomas; Cindy A Evrard; David R Jones; Andrea R Masters; David M Haas; Laura S Haneline; Sara K Quinney
Journal:  Am J Perinatol       Date:  2020-02-12       Impact factor: 3.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.